← All trials
NCT07053150
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 15, 2025
- Primary completion
- Dec 31, 2030
- Completion date
- Apr 1, 2031
- First posted
- Jul 8, 2025
- Last posted
- Jul 8, 2025
- Enrollment
- 80
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Huazhong University of Science and TechnologyLead sponsor
- Huazhong University of Science and TechnologyOfficial
- Innovent Biologics (Suzhou) Co. Ltd.Collaborator
- Hengrui Therapeutics, Inc.Collaborator
- Huazhong University of Science and TechnologySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.